Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?

Bonanni, Michela; Rehak, Laura; Massaro, Gianluca; Benedetto, Daniela; Matteucci, Andrea; Russo, Giulio; Esperto, Francesco; Federici, Massimo; Mauriello, Alessandro; Sangiorgi, Giuseppe

doi:10.3390/biomedicines10051091

Cited by 2 publications

(1 citation statement)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The types of stem cells used in ED treatment include autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) and autologous adipose-Information Classification: General derived stem cells (ADSCs). Due to their low immunogenicity, several perinatal tissue-derived cells or bioactive factors, such as hUCBSCs, Wharton's Jelly-derived mesenchymal stem cells, placental matrix-derived mesenchymal stem cells (PL-MSCs) [28,46,[52][53][54][55], and acellular solutions from umbilical cord tissue, have also been used as an allogeneic source for ED treatment.…”

Section: Type Of Stem Cells Used In Clinical Trials For Edmentioning

confidence: 99%

Recent advances in stem cell therapy for erectile dysfunction: a narrative review

Wang

Gao

Zheng

et al. 2023

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: While phosphodiesterase type 5 inhibitors (PDE5is) and others are used to treat Erectile dysfunction (ED), many patients are either unresponsive or resistant to it. Stem cell therapy (SCT) is a promising alternative approach. Numerous preclinical trials have demonstrated improved erectile function in animal models using SCT, although the number of clinical trials investigating SCT for men with ED is limited. Nonetheless, findings from human clinical trials suggest that SCT may be a useful treatment option.Areas covered: Biomedical literature, including PubMed, ClinicalTrials.gov, and European Union Clinical Trails Registry, were analyzed to summarize and synthesize information on stem cell therapy for ED in this narrative review. The achievements in preclinical and clinical evaluations are presented and critically analyzed.Expert opinion: SCT has demonstrated some benefits in improving erectile function, while further studies are urgently needed. Such studies would provide valuable insights into the optimal use of stem cell therapy and its potential as a therapeutic option for ED. Taking advantage of different mechanisms of action involved in various regenerative therapies, combination therapies such as SCT and low-energy shock waves or platelet-rich plasma may provide a more effective therapy and warrant further research.

show abstract

Section: Type Of Stem Cells Used In Clinical Trials For Edmentioning

confidence: 99%

Recent advances in stem cell therapy for erectile dysfunction: a narrative review

Wang

Gao

Zheng

et al. 2023

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Analyzing the Current Umbilical Cord-derived Mesenchymal Stem Cell Secretome Evidence for Erectile Dysfunction Management

Margiana,

Abdullah,

Pakpahan

et al. 2023

Biomolecular and Health Science Journal

View full text Add to dashboard Cite

Erectile dysfunction (ED) impacts millions of men, especially older men, and current treatment options, including tadalafil, phosphodiesterase type 5 inhibitors, and short-acting testosterone, are ineffective. This necessitates the immediate development of effective alternative ED treatments. In recent years, attention has been drawn to the secretome of umbilical cord-derived mesenchymal stem cells (UC-MSCs) due to its anti-inflammatory and immunomodulatory properties, which can reduce inflammation and promote tissue repair. The UC-MSCs secretome contains numerous growth factors, such as vascular endothelial growth factor, insulin-like growth factor 1 (IGF-1), and basic fibroblast growth factor (bFGF), which are essential for promoting endothelial cell proliferation and penile blood flow. This review seeks to examine the existing evidence on the use of stem cells, with a focus on UC-MSCs secretome, as a potential treatment modality for erectile dysfunction (ED). By reviewing the PubMed, Google Scholar, and Scopus databases, a comprehensive narrative review was conducted. Included among the search queries were "erectile dysfunction," "stem cells," "mesenchymal stem cells," "umbilical cord," and "secretome." Only research published in English within the past decade was included in the analysis. The findings indicate that the secretome of UC-MSCs has promise for treating ED. The secretome is composed of growth factors, cytokines, and other bioactive compounds that promote tissue repair and regeneration via paracrine effects on adjacent cells. The administration of UC-MSCs improved erectile function, penile blood flow, and smooth muscle content. In addition, discarded UC-MSCs serve as a cost-effective and copious source of ethically acceptable and immunogenic UC-MSCs with low immunogenicity. The secretome of UC-MSCs offers a potential therapeutic strategy for treating erectile dysfunction. However, further preclinical and clinical research must be done to determine the safety and efficacy of stem cell-based treatments for erectile dysfunction.

show abstract

Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?

Cited by 2 publications

References 104 publications

Recent advances in stem cell therapy for erectile dysfunction: a narrative review

Recent advances in stem cell therapy for erectile dysfunction: a narrative review

Analyzing the Current Umbilical Cord-derived Mesenchymal Stem Cell Secretome Evidence for Erectile Dysfunction Management

Contact Info

Product

Resources

About